Cellectis S.A. to Present Data on its Allogeneic CAR T Cell Programs at American Society of Gene & Cell Therapy Annual Meeting
Published on May 08, 2015
May 7, 2015 – New York (USA) – Cellectis S.A. (Alternext: ALCLS – Nasdaq Global Market: CLLS), a pioneering gene-editing company employing proprietary technologies to develop best-in-class products in the emerging field of immuno-oncology, today announced that pre-clinical data on its engineered allogeneic CAR T-cells will be featured in an oral presentation at the American Society of Gene & Cell Therapy (ASGCT) 18th Annual Meeting. The meeting will be held from May 13 to 16, 2015 in New Orleans, LA.
The company will also have three posters that will present how its gene editing technologies, including TALEN®, could enable the efficient manufacture of "off-the-shelf" CAR T-cells.
The selected presentations include:
- UCART19, an Allogeneic “Off-the-Shelf” Adoptive T-Cell Immunotherapy Against CD19+ B-Cell Leukemias
Oral Presentation - Session title: Cancer – Immunotherapy, Cancer Vaccines II
Presentation Time: Saturday, May 16, 2015, 10:30 am to 10:45 am
- Targeted Genome Modifications for Improved Adoptive Immunotherapy
Poster Session: Gene Targeting and Gene Correction II
Presentation Time: Thursday, May 14, 2015, 5:30 pm to 7:00 pm
- A Multidrug Resistant Engineered CAR T-Cell for Allogeneic Combination Immunotherapy
Poster Session: Cancer – Immunotherapy, Cancer Vaccines II
Presentation Time: Thursday, May 14, 2015 - 5:30 pm to 7:00 pm
- Allogeneic CAR T-Cells Targeting CD123 for Adoptive Immunotherapy of Acute Myeloid Leukemia (AML)
Poster Session: Cancer – Immunotherapy, Cancer Vaccines II
Presentation Time: Thursday, May 14, 2015 - 5:30 pm to 7:00 pm
Posters will be posted on Cellectis’ website on May 13, 2015.